Management of advanced bladder cancer in patients with impaired renal function.

abstract：:Sinonasal malignancies continue to have poor survival rates. Disease-related mortality is usually the result of disease recurrence and progression at the primary site despite aggressive therapy. Complete surgical excision with postoperative radiation therapy remains the standard of care for resectable lesions. Improve...

journal_title：Expert review of anticancer therapy

authors： Maghami E,Kraus DH

更新日期：2004-06-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...

journal_title：Expert review of anticancer therapy

authors： Metro G,Crinò L

更新日期：2011-05-01 00:00:00

abstract：BACKGROUND:Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC). This retrospective study evaluated patterns of liver toxicity in patients treated with FOLinic acid, Fluorouracil, IRInotecan (FOLFIRI)-based regimens. METHOD...

journal_title：Expert review of anticancer therapy

authors： Vincenzi B,Imperatori M,Picardi A,Vespasiani Gentilucci U,Gallo P,Fausti V,Spalato Ceruso M,Santini D,Tonini G

更新日期：2015-01-01 00:00:00

abstract：:Today dermoscopy is standard-of-care in the diagnosis and management of patients with benign and malignant skin tumors because it increases the diagnostic accuracy of skin lesions compared to the naked-eye examination up to 25%. Despite its role in the routine dermato-oncology, it increasingly gained interest as a bri...

journal_title：Expert review of anticancer therapy

authors： Woltsche N,Schwab C,Deinlein T,Hofmann-Wellenhof R,Zalaudek I

更新日期：2016-05-01 00:00:00

abstract：:Until recently, cytokine therapy has been the only validated option for patients with advanced renal cancer. IFN-alpha is one of very few treatments that have demonstrated improved median survival compared with the appropriate control. In patients with synchronous metastases at diagnosis, debulking nephrectomy prior t...

journal_title：Expert review of anticancer therapy

authors： Coppin C

更新日期：2008-06-01 00:00:00

abstract：:Testicular germ cell tumors are the most frequent solid tumor to affect young adult males and are increasing in incidence for reasons that are poorly understood. Increasingly, patients present with localized disease where disease-specific survival approaches 100%. Even in the presence of metastatic disease, the majori...

journal_title：Expert review of anticancer therapy

authors： Gilbert DC,Van As NJ,Huddart RA

更新日期：2009-02-01 00:00:00

abstract：:For many decades, the use of chemotherapy as second-line therapy in non-small-cell lung cancer relied upon disease progression. Several studies have shown that four to six cycles of chemotherapy administered as front-line therapy treatment offers a survival advantage to patients; however, further chemotherapy beyond t...

journal_title：Expert review of anticancer therapy

authors： Velez M,Belalcazar A,Domingo G,Blaya M,Raez LE,Santos ES

更新日期：2010-04-01 00:00:00

abstract：:Rapid malignant proliferation, prior to effective tumor neoangiogenesis, creates a microenvironment around solid cancers, which is predominantly hypoxic and characterized by a high interstitial fluid pressure. Presumably as an adaptive response, tumor cells favor metabolic activity with apparently inefficient energy o...

journal_title：Expert review of anticancer therapy

authors： Abaza M,Luqmani YA

更新日期：2013-10-01 00:00:00

abstract：:Current targeted strategies for cancer focus on the blockade of growth factor receptors and the inhibition of angiogenesis. The VEGF pathway has become an attractive target in multiple malignancies, including lung cancer. Bevacizumab, a monoclonal antibody against VEGF, increased survival in non-small-cell lung cancer...

journal_title：Expert review of anticancer therapy

authors： Planchard D

更新日期：2011-08-01 00:00:00

abstract：:Cancer immunotherapy aims at eliciting an immune response directed against tumor antigens to help fight off residual tumor cells and, thereby, improve the survival and quality of life of cancer patients. Different immunotherapeutic approaches share the use of dendritic cells (DCs) to present tumor-associated antigens ...

journal_title：Expert review of anticancer therapy

authors： Tyagi RK,Mangal S,Garg N,Sharma PK

更新日期：2009-01-01 00:00:00

abstract：:Anemia is a frequent problem in cancer patients, especially in those treated with chemotherapy, and has an important negative impact on quality of life. Red blood cell transfusions provide clear but rather temporary comfort. The development of erythropoietic stimulating agents (ESAs) led to a more durable anemia treat...

journal_title：Expert review of anticancer therapy

authors： Vansteenkiste J,Wauters I

更新日期：2007-10-01 00:00:00

abstract：:Ca(2+) influx at critical points in the cell cycle is required for proliferation. This requirement is so ubiquitous that its occurrence is often treated as background noise. Yet without it, cells stop dividing, suggesting an obvious and potentially effective way to treat cancer. To control proliferation by controlling...

journal_title：Expert review of anticancer therapy

authors： Gray LS,Schiff D,Macdonald TL

更新日期：2013-05-01 00:00:00

abstract：:More than 13,000 patients died from invasive bladder cancer in 2005 alone. Radical cystectomy is the most commonly prescribed treatment for patients with muscle-invasive bladder cancer, or for those with a nonmuscle-invasive disease that is refractory to intravesical therapy. Despite advances in surgical technique and...

journal_title：Expert review of anticancer therapy

authors： Amiel GE,Lerner SP

更新日期：2006-02-01 00:00:00

abstract：:Approximately 25% of breast cancer patients without lymph node metastases develop systemic relapse. A growing body of data supports the notion that hematogenous dissemination of breast cancer cells occurs independently of lymphatic spread of disease; however, current clinical practice does not involve routine analysis...

journal_title：Expert review of anticancer therapy

authors： Lang JE,Hall CS,Singh B,Lucci A

更新日期：2007-10-01 00:00:00

abstract：:Limb-salvage surgery plays a major role in the management of patients with osteosarcoma. As prognosis improves, reconstructive options have come under greater scrutiny with regard to their durability and functionality. The advent of computer navigation-guided reconstruction is discussed in detail, along with methods b...

journal_title：Expert review of anticancer therapy

authors： Mangat KS,Jeys LM,Carter SR

更新日期：2011-02-01 00:00:00

abstract：INTRODUCTION:Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immun...

journal_title：Expert review of anticancer therapy

authors： Kamath SD,Kalyan A,Benson AB 3rd

更新日期：2018-12-01 00:00:00

abstract：INTRODUCTION:The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worseni...

journal_title：Expert review of anticancer therapy

authors： Donini M,Buti S,Massari F,Mollica V,Rizzo A,Montironi R,Bersanelli M,Santoni M

更新日期：2020-06-01 00:00:00

abstract：:Recurrent non muscle invasive bladder cancer (NMIBC) represents a therapeutic challenge, especially in the case of Bacillus Calmette Guerin (BCG)-failures. Chemohyperthermia (CHT) has been tested as adjuvant therapy in selected categories of patients with promising results. The aim of this systematic review is to expl...

journal_title：Expert review of anticancer therapy

authors： Soria F,Allasia M,Oderda M,Gontero P

更新日期：2016-01-01 00:00:00

abstract：:Bladder cancer is the most frequently occurring tumor of the urinary system, with over 10,000 new diagnoses each year in the UK. Approximately 70% of these are non-muscle-invasive and limited to the mucosa (Ta) or submucosa (T1). These tumors are generally managed with transurethral resection followed by adjuvant intr...

journal_title：Expert review of anticancer therapy

authors： Cheung G,Dasgupta P,Guru KA,Billia M,Khan MS

更新日期：2012-06-01 00:00:00

abstract：INTRODUCTION:Hormone receptor positive (HR+) breast cancer represents the most common subtype of breast cancer. Metastatic HR+ breast cancer may develop resistance to standard hormone therapies, arising from genomic alterations in the estrogen receptor and/or upregulation of other signal transduction pathways. Areas co...

journal_title：Expert review of anticancer therapy

authors： Vidula N,Rugo HS

更新日期：2018-01-01 00:00:00

abstract：INTRODUCTION:The therapeutic armamentarium for advanced soft tissue sarcoma (STS) has increased over the last few years. Doxorubicin monotherapy or in combination is now the established first line treatment. Beyond first line treatment, no standard therapy has been established. Novel drugs have reached the late-clinica...

journal_title：Expert review of anticancer therapy

authors： Skafida E,Kokkali S,Nikolaou M,Digklia A

更新日期：2017-06-01 00:00:00

abstract：:Despite being a common cancer worldwide, management of transitional cell carcinoma of the bladder currently relies primarily on clinical staging and histopathologic parameters. Assaying alterations in molecular pathways can contribute valuable information that can accurately predict outcome and chemotherapeutic respon...

journal_title：Expert review of anticancer therapy

authors： Bartsch G,Mitra AP,Cote RJ

更新日期：2010-12-01 00:00:00

abstract：INTRODUCTION:Germ cell tumors (GCTs) are the most common solid malignancies in young men. The overall cure rate of GCT patients in metastatic stage is excellent, however; patients with relapsed or refractory disease have poor prognosis. Attempts to treat refractory disease with novel effective treatment to improve prog...

journal_title：Expert review of anticancer therapy

authors： Kozakova K,Mego M,Cheng L,Chovanec M

更新日期：2020-11-02 00:00:00

abstract：INTRODUCTION:Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until in...

journal_title：Expert review of anticancer therapy

authors： Manceau C,Mourey L,Pouessel D,Ploussard G

更新日期：2020-08-01 00:00:00

abstract：:There is increasing interest in the use of prognostic markers that may predict survival and guide management in patients diagnosed with the early stages of chronic lymphocytic leukemia (CLL). Currently, the most important traditional prognostic factors include clinical staging, lymphocyte doubling time and β2-microglo...

journal_title：Expert review of anticancer therapy

authors： Bazargan A,Tam CS,Keating MJ

更新日期：2012-03-01 00:00:00

abstract：:Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis. In addition, limited active therapeutic options are available. The cytotoxic drug gemcitabine and the inhibition of the mTOR pathway have demonstrated modest activity in sarcomas as monotherapy. However, prec...

journal_title：Expert review of anticancer therapy

authors： Martin-Liberal J,Tirado OM,García del Muro X

更新日期：2015-03-01 00:00:00

abstract：INTRODUCTION:Angiogenesis is critical for tumor growth, proliferation and metastasis with the crucial role of Vascular Endothelial Growth factor (VEGF) pathway. Ramucirumab is a monoclonal antibody that specifically targets the extracellular domain of Vascular Endothelial Growth Factor Receptor 2. Areas covered: We per...

journal_title：Expert review of anticancer therapy

authors： Paulus V,Avrillon V,Pérol M

更新日期：2016-11-01 00:00:00

abstract：:Lymph node dissection in bladder cancer is an integral part of radical cystectomy. It allows for accurate staging of the patient and will, therefore, serve to dictate additional treatment and add prognostic information. The issue of what is an adequate lymphadenectomy as to the extent and boundaries of the operation, ...

journal_title：Expert review of anticancer therapy

authors： Ghavamian R,Hakimi AA

更新日期：2009-12-01 00:00:00

abstract：:Borderline ovarian tumors (BOTs) are epithelial tumors of the ovaries characterized by cellular proliferation and nuclear atypia but without an infiltrative growth pattern. As they frequently affect younger patients the clinical management is complicated by considerations such as preserving fertility and reducing post...

journal_title：Expert review of anticancer therapy

authors： Trillsch F,Mahner S,Ruetzel J,Harter P,Ewald-Riegler N,Jaenicke F,du Bois A

更新日期：2010-07-01 00:00:00

abstract：:Acute myeloid leukemia (AML) is a hematologic malignancy with a peak incidence over the age of 55 years. AML of older patients is less curable with conventional chemotherapy, and, when it relapses, is almost uniformly fatal. Novel treatments hold the promise of improving the results of therapy, but have failed so far ...

journal_title：Expert review of anticancer therapy

authors： Lekakis L,de Lima M

更新日期：2008-05-01 00:00:00